logo-loader
HealthPharma & Biotech
viewCello Health PLC

Cello Group’s Scott: Share price still too low despite recent rise

< id="YT_video" object width="560" height="315">

Cello Group (LON:CLL) chief executive Mark Scott claims that his healthcare and consumer strategic marketing group is still undervalued even after several years of share price growth.

He says that while there are a number of quoted health services like it in the States, Cello is the only one on the London market and trades on much lower earnings multiples than its US peers.

He says the main source of growth is organic, but the company will look at potential acquisitions if opportunities arise. 

Quick facts: Cello Health PLC

Price: 126.5 GBX

AIM:CLL
Market: AIM
Market Cap: £134.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016

RNS

Holding(s) in Company

2 weeks, 1 day ago

Total Voting Rights

2 weeks, 1 day ago

Disposal

2 weeks, 6 days ago

Interim Results

on 09/18/2019

Holding(s) in Company

on 08/23/2019

Acquisition of ISS

on 08/16/2019

Total Voting Rights

on 08/06/2019

2 min read